BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Liraglutide (Victoza) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Liraglutide (Victoza)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03856632-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Liraglutide (Victoza): Phase 4 readout est. (NCT03856632)
DESCRIPTION:Liraglutide (Victoza)\, phase 4.\nStudy: Liraglutide Effect in 
 Atrial Fibrillation\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/liraglutide-victoza#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT03856632
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06361238-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Liraglutide (Victoza): Phase 3 readout est. (NCT06361238)
DESCRIPTION:Liraglutide (Victoza)\, phase 3.\nStudy: Liraglutide in Prevent
 ing Delirium in Diabetic Elderly After Cardiac Surgery\nEstimated primary 
 completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/liraglutide-victoza#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06361238
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04575844-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Liraglutide (Victoza): Phase 4 readout est. (NCT04575844)
DESCRIPTION:Liraglutide (Victoza)\, phase 4.\nStudy: Effects of Exercise an
 d GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Ad
 ults With Metabolic Syndrome\nEstimated primary completion: 30 April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide-victoza#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0457
 5844
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03883412-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Liraglutide (Victoza): Phase 4 readout est. (NCT03883412)
DESCRIPTION:Liraglutide (Victoza)\, phase 4\, Type 2 Diabetes.\nStudy: Effe
 ct of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sens
 itivity in Type 2 Diabetes ( ZQL007)\nEstimated primary completion: June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide-vict
 oza#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03883412
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244003-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Liraglutide (Victoza): Phase 4 readout est. (NCT07244003)
DESCRIPTION:Liraglutide (Victoza)\, phase 4\, Type 2 Diabetes.\nStudy: Effi
 cacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabete
 s With Poor Glycemic Control\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/liraglutide-victo
 za#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7244003
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681299-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Liraglutide (Victoza): Phase 4 readout est. (NCT05681299)
DESCRIPTION:Liraglutide (Victoza)\, phase 4.\nStudy: Effects of GH and Lirg
 lutide on AgRP\nEstimated primary completion: 30 April 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/liraglutide-victoza#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05681299
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976619-116@assetmemo.bio
DTSTAMP:20261121T005026Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Liraglutide (Victoza): Phase 2 readout est. (NCT06976619)
DESCRIPTION:Liraglutide (Victoza)\, phase 2\, Type 2 Diabetes.\nStudy: The 
 Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in
  People With Type 1 and Type 2 Diabetes\nEstimated primary completion: 30 
 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/liraglu
 tide-victoza#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06976619
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
